Australia markets closed

Teva Pharmaceutical Industries Limited (TEVA)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
13.90+0.65 (+4.92%)
As of 02:34PM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 14.78B
Enterprise value 31.71B
Trailing P/E 872.00
Forward P/E 5.57
PEG ratio (5-yr expected) N/A
Price/sales (ttm)0.94
Price/book (mrq)2.00
Enterprise value/revenue 2.00
Enterprise value/EBITDA 20.35

Trading information

Stock price history

Beta (5Y monthly) 1.06
52-week change 351.78%
S&P500 52-week change 321.08%
52-week high 314.47
52-week low 37.09
50-day moving average 313.48
200-day moving average 310.77

Share statistics

Avg vol (3-month) 310.1M
Avg vol (10-day) 39.54M
Shares outstanding 51.13B
Implied shares outstanding 61.13B
Float 81.11B
% held by insiders 10.00%
% held by institutions 152.68%
Shares short (15 Apr 2024) 411.56M
Short ratio (15 Apr 2024) 41.41
Short % of float (15 Apr 2024) 4N/A
Short % of shares outstanding (15 Apr 2024) 41.03%
Shares short (prior month 15 Mar 2024) 410.46M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 42.95
Payout ratio 40.00%
Dividend date 312 Dec 2017
Ex-dividend date 427 Nov 2017
Last split factor 22:1
Last split date 301 July 2004

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -3.53%
Operating margin (ttm)28.05%

Management effectiveness

Return on assets (ttm)4.54%
Return on equity (ttm)-7.36%

Income statement

Revenue (ttm)15.85B
Revenue per share (ttm)14.16
Quarterly revenue growth (yoy)14.80%
Gross profit (ttm)N/A
EBITDA 4.33B
Net income avi to common (ttm)-559M
Diluted EPS (ttm)-0.50
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)3.23B
Total cash per share (mrq)2.88
Total debt (mrq)20.27B
Total debt/equity (mrq)249.48%
Current ratio (mrq)1.02
Book value per share (mrq)6.70

Cash flow statement

Operating cash flow (ttm)1.37B
Levered free cash flow (ttm)3.29B